Achillion stock plunges as FDA maintains clinical hold on hep C drug

Achillion stock plunges as FDA maintains clinical hold on hep C drug

The FDA asked the company to halt development of sovaprevir in June, after detecting elevated liver enzymes, an indication of liver damage, in multiple patients who were given the drug in a clinical study. The regulator asked for some clinical data on

10
Like
Save

Comments

Write a comment

*